This is a pilot acute dietary intervention study with a randomized cross-over design aiming to investigate whether acute supplementation of extra virgin olive oil (EVOO) rich in oleocanthal could attenuate postprandial hyperglycemia and activation of platelets in T2DM patients. For this reason, non-insulin dependent diabetic patients (10-15) will be randomly assigned to consume in five different days white bread (50 g CHO) with butter, butter with ibuprofen, refined olive oil and olive oil with oleocanthal (250 mg/Kg 500 mg/Kg). Blood samples will be collected pre- and post-intervention up to 4 hours in order to determine platelet aggregation, postprnadial glycemia, lipemia, inflammation and oxidative stress. Taking into account the strong anti-inflammatory and anti-platelet properties of oleocanthal, this study will assess whether oleocanthal-rich olive oils could exert similar effects under real in vivo conditions in T2DM patients. It will also assess whether these effects are achieved through improvement of postprandial glycemia and lipemia.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Change from baseline of ADP-induced platelet aggregation at 90 min after meals consumption
Timeframe: 0 and 90 after the consumption of each type of meal
Change from baseline of ADP-induced platelet aggregation at 240 min after meals consumption
Timeframe: 0 and 240 after the consumption of each type of meal
Change from baseline of TRAP-induced platelet aggregation at 90 min after meals consumption
Timeframe: 0 and 90 after the consumption of each type of meal
Change from baseline of TRAP-induced platelet aggregation at 240 min after meals consumption
Timeframe: 0 and 240 after the consumption of each type of meal
Change from baseline of PAF-induced platelet aggregation at 90 min after meals consumption
Timeframe: 0 and 90 after the consumption of each type of meal
Change from baseline of PAF-induced platelet aggregation at 240 min after meals consumption
Timeframe: 0 and 240 after the consumption of each type of meal
Incremental Area Under the Serum Concentration Versus Time Curve (AUC) of Glucose
Timeframe: 0, 15, 30, 60, 90 120, 180, 240 min after the consumption of each meal
Incremental Area Under the Serum Concentration Versus Time Curve (AUC) of Insulin
Timeframe: 0, 15, 30, 60, 90 120, 180, 240 min after the consumption of each meal
Incremental Area Under the Serum Concentration Versus Time Curve (AUC) of Triglycerides
Timeframe: 0, 15, 30, 60, 90 120, 180, 240 min after the consumption of each meal